Indications for FELBATOL SUSPENSION:
Not a first-line treatment. Partial seizures with or without generalization in adults. Adjunct in Lennox-Gastaut syndrome in children.
See full labeling. ≥14yrs: initial monotherapy: 1.2g/day in 3–4 divided doses, increase by 600mg every 2 weeks to 2.4g/day and up to 3.6g/day if needed. Conversion to monotherapy/adjunctive therapy: 1.2g/day in 3–4 divided doses, increase to 2.4g/day at week 2, and to 3.6g/day at week 3. Dosages of concomitant anticonvulsant drugs should be reduced upon the initiation of felbamate therapy and weekly thereafter (see full labeling). Renal dysfunction: reduce initial and maintenance dose by ½.
Lennox-Gastaut: ≥2yrs: 15mg/kg per day in 3–4 divided doses, increase dose by 15mg/kg per day at 1 week intervals to 45mg/kg per day. Dose of concomitant anticonvulsant drug should be reduced upon the initiation of felbamate therapy (see full labeling).
FELBATOL SUSPENSION Contraindications:
History of hepatic dysfunction or blood dyscrasias.
Aplastic anemia. Hepatic failure.
FELBATOL SUSPENSION Warnings/Precautions:
Increased risk of aplastic anemia or hepatic failure. Do full baseline hematologic evaluations and hepatic function tests before, during, and after therapy; discontinue if hepatic tests are abnormal or bone marrow depression occurs; consult hematologist if hematological abnormalities occur. Suicidal tendencies (monitor). Adjust dose of and monitor other anticonvulsants. Avoid abrupt cessation. Obtain written informed consent. Pregnancy (Cat.C). Nursing mothers.
FELBATOL SUSPENSION Classification:
FELBATOL SUSPENSION Interactions:
Increases serum levels of phenytoin, valproate, carbamazepine metabolite. Decreases carbamazepine levels. Serum levels decreased by phenytoin, carbamazepine.
Anorexia, vomiting, insomnia, nausea, headache; rare: primary hepatotoxicity, aplastic anemia.
Generic Drug Availability:
Tabs—100; Susp—4oz, 8oz, 32oz